2019
DOI: 10.5455/im.36591
|View full text |Cite
|
Sign up to set email alerts
|

The pitfalls of crowdfunding Alzheimer's disease research

Abstract: With pharmaceutical companies' repeated failures at finding effective interventions for Alzheimer's disease, together with an increasing reliance on the growing federal funding for research, there is an emergent opportunity for financing alternate research through crowdfunding. Crowdfunding-where funding is obtained from small donations from a large group of people-has become a new source of funding for medical research. By understanding how the research community has evolved to study Alzheimer's disease the p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 62 publications
(78 reference statements)
0
1
0
Order By: Relevance
“…This is difficult to understand both clinically and statistically how we got to a situation where the government approves a drug that is both minimal useful and extraordinarily dangerous, and if economically successful will bankrupt Medicare [69]. A quick review of the researchers involved in the FDA's decision shows conflicts of interest [70]. Predictions indicate that by prescribing Aduhelm, Medicare will be paying nearly $29 billion in just one year matching three-quarters of Medicare's total spending for all Part B drugs [71].…”
Section: Medicationsmentioning
confidence: 99%
“…This is difficult to understand both clinically and statistically how we got to a situation where the government approves a drug that is both minimal useful and extraordinarily dangerous, and if economically successful will bankrupt Medicare [69]. A quick review of the researchers involved in the FDA's decision shows conflicts of interest [70]. Predictions indicate that by prescribing Aduhelm, Medicare will be paying nearly $29 billion in just one year matching three-quarters of Medicare's total spending for all Part B drugs [71].…”
Section: Medicationsmentioning
confidence: 99%